Shacham Sharon

SEC source: 0000905148-26-003041 · form4.xml · derivative · entry 1

Shacham Sharon · CIK 0001588438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,275

Underlying: Common Stock · 20,275 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

SEC source: 0000905148-26-002562 · form4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,366

F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000905148-25-002173 · form4.xml · derivative · entry 1

Shacham Sharon · CIK 0001588438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,275

Underlying: Common Stock · 20,275 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

SEC source: 0000905148-24-001776 · form4.xml · derivative · entry 1

Shacham Sharon · CIK 0001588438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,275

Underlying: Common Stock · 20,275 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-22-057405 · doc4.xml · derivative · entry 1

Shacham Sharon · CIK 0001588438 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,235

Underlying: Common Stock · 35,235 shares

Expires 2032-11-13

F1 · derivative.exercise_date: The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001209191-22-021755 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2032-03-28

F2 · derivative.exercise_date: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-021755 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 958,131

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014626 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-02-27

F5 · derivative.exercise_date: This option was granted to the spouse of the reporting person on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014626 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 713,757

F4 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014626 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 719,983

F3 · shares: Represents the award of restricted stock units ("RSUs") to the spouse of the reporting person pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014626 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 898,131

F1 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-011639 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 698,983

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-011639 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 904,357

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008119 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 708,062

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008119 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 913,445

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-022487 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 714,826

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.29 to $12.56, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-015482 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 153,500

Underlying: Common Stock · 153,500 shares

Expires 2031-02-24

F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-015482 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,500

Underlying: Common Stock · 153,500 shares

Expires 2031-02-24

F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-015482 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 718,826

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.

F3 · balance_after: The spouse of the reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 575,126 shares of common stock.

SEC source: 0001209191-21-015482 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 920,152

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.

F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 776,452 shares of common stock.

SEC source: 0001209191-21-012964 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 575,126

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-012964 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 776,452

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011486 · doc4.xml · derivative · entry 6

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 43,600

Underlying: Common Stock · 21,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F7 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F7 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-011486 · doc4.xml · derivative · entry 5

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,600

Underlying: Common Stock · 21,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F6 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F6 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 584,621

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 785,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 562,821

F4 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F5 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 764,147

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-009073 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 42,900

Underlying: Common Stock · 14,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On February 5, 2020, the spouse of the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009073 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,900

Underlying: Common Stock · 14,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 57,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-21-009073 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 569,422

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-21-009073 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 770,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-054821 · doc4.xml · derivative · entry 6

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,076 shares

Expires 2020-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-054821 · doc4.xml · derivative · entry 5

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,424 shares

Expires 2020-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-054821 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756,489

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.71 to $15.16, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-054821 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 763,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-054821 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 757,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-047278 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,076

Underlying: Common Stock · 1,477 shares

Expires 2020-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-047278 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756,489

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-047278 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 757,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-042840 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,424

Underlying: Common Stock · 7,500 shares

Expires 2020-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-042840 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756,489

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.17 to $19.86, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-042840 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 763,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-042309 · doc4.xml · derivative · entry 7

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 333,561

Underlying: Common Stock · 7,500 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F6 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-042309 · doc4.xml · nonDerivative · entry 5

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 555,122

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F5 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.73, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-042309 · doc4.xml · nonDerivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 555,422

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.64, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-042309 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 562,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

SEC source: 0001209191-20-042309 · doc4.xml · derivative · entry 6

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,803

Underlying: Common Stock · 7,500 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-042309 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756,489

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.30 to $19.75, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-042309 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 763,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.